NTRK1 and neoplasm: Larotrectinib, a highly selective small-molecule inhibitor of tropomyosin receptor kinase (TRK) showed rapid and durable responses with a high tumor control rate and good tolerability in TRK fusion-positive primary central nervous system tumors in adult and pediatric patients [39].